The FDA is drafting guidelines for medical device and drug makers concerning the portrayal of information on advertisements about their products. What’s interesting about this move is that, in addition to the usual information regarding the use of outright bogus claims as a violation of FDA rules, the agency also advises against the use of stubtle advertising techniques which may portray a drug or device as wholly benign amid known adverse effects and rigorous monitoring schedules — a practice they say is “deceptive” and “discordant”. | PDF LINK
Related Posts Within Doctor Pundit:
Originating from Saint Paul, Minnesota, [doctorpundit.com] is a weblog about the policy of healthcare and where it intersects with politics and public opinion; it is edited by Michael Douglas, MD, MBA. Welcome, and please consider my take on what is Healthcare 2.0, complemented by a few of my thoughts on my personal avocations and guilty pleasures: music, prose, and writing. Follow Doctor Pundit via RSS above.
North, GA #hospital job for Physical Therapist #jobs on 2/7 - @careerbarn Details http://t.co/wORGjzp9
RT @RichmondDoc: In the absence of #MDChat, should you be interested: @NPALive is covering a health policy conference call with Dr. Ezekiel Emmanuel.
Grant Will Aid Hunterdon Medical Center for Community Needs Program http://t.co/FliewVHM #hitc #hcsm
RT @HealthIsSocial: RT @farristimimi: Psychologists Debate Social Media's Role in Suicide Interventions
http://t.co/tG2eFCkv #hcsm #mhsm #mentalhealth #hcsmca
RT @pjmachado Just ask what they want... RT @dsgold Consumers aren't too keen on personalized search results http://t.co/JZT0Whxr #hcsm
DOCTOR PUNDIT @ ONE YEAR | An occasional DP series from 2010 highlighting healthcare policy trends over the period from 2009-2010 in a compare/contrast format.
